Innovation Pharmaceuticals enters research collaboration with USP

The Company and University of Sao Paulo, Brazil, have entered into a collaborative research agreement to investigate the broad-spectrum activity and treatment potential of Brilacidin in fungal diseases. Under terms of the agreement, USP researchers are to conduct pre-clinical efficacy, mechanism, resistance and immunological studies of Brilacidin against Aspergillosis, Cryptococcus and Candida. Separate in vitro testing of Brilacidin’s antifungal properties is underway by NIH/NIAID-affiliated researchers, with potential to bridge into in vivo models, formulation development support and clinical testing.